A pediatric patient may be a candidate to receive a vaccine against dengue fever.

The vaccine is a live-attenuated vaccine.


Indications for use of the Dengvaxia vaccine - all of the following:

(1) pediatric patient from 9 to 16 years of age

(2) living in an area where dengue is endemic

(3) confirmation of a previous infection (highly-specificserodiagnostic test, etc)


The vaccine is given in 3 doses, each 6 months apart.



(1) severe allergic reaction to any component of the vaccine

(2) severe immunodeficiency or immunosuppression

(2a) HIV infection with CD4+ lymphocyte count < 200 per microliter


Vaccination of a sero-negative patient may be associated with severe disease if the patient is re-exposed to natural dengue.

To read more or access our algorithms and calculators, please log in or register.